Payment overview · 2025
General Payments
$1,337.90
52 reported records · 8 companies
Healthcare provider profile · identity verified
Phi Van Tran, MD
Allopathic & Osteopathic Physicians|Family Medicine · LAWRENCE, MA · NPI 1124092929
Verified facts
What the public records show
CMS Open Payments records show Phi Van Tran, MD received $1,337.90 in general payments during 2025 across 52 reported records.
AstraZeneca Pharmaceuticals LP accounted for 64.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 243 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 248 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vemlidy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 248 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 332 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $860.65 | 64.3% | 29 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $176.12 | 13.2% | 9 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $141.98 | 10.6% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.09 | 3.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.51 | 3.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.90 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.17 | 1.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.48 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,337.90 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $409.58 | 16 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $408.47 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $243.14 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $176.12 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $73.99 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.51 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 243 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 248 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
243 | 55 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
248 | 45 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
248 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
332 | 57 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
145 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1325 | 338 |
| Amlodipine Besylate | Amlodipine Besylate | 817 | 206 |
| Losartan Potassium | Losartan Potassium | 773 | 194 |
| Fluticasone Propionate | Fluticasone Propionate | 762 | 244 |
| Lisinopril | Lisinopril | 755 | 198 |
| Metformin Hcl | Metformin Hcl | 730 | 183 |
| Gabapentin | Gabapentin | 721 | 203 |
| Omeprazole | Omeprazole | 720 | 213 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 620 | 104 |
| Simvastatin | Simvastatin | 529 | 137 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 522 | 193 |
| Metoprolol Succinate | Metoprolol Succinate | 512 | 118 |
| Tamsulosin Hcl | Tamsulosin Hcl | 358 | 95 |
| Trulicity | Dulaglutide | 332 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 267 | 69 |
| Jardiance | Empagliflozin | 248 | 45 |
| Farxiga | Dapagliflozin Propanediol | 243 | 55 |
| Mirtazapine | Mirtazapine | 243 | 70 |
| Diclofenac Sodium | Diclofenac Sodium | 237 | 65 |
| Ketoconazole | Ketoconazole | 227 | 47 |
| Finasteride | Finasteride | 194 | 49 |
| Ibuprofen | Ibuprofen | 172 | 105 |
| Pantoprazole Sodium | Pantoprazole Sodium | 159 | 53 |
| Famotidine | Famotidine | 158 | 56 |
| Ropinirole Hcl | Ropinirole Hcl | 156 | 51 |
| Allopurinol | Allopurinol | 155 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 152 | 36 |
| Eliquis | Apixaban | 145 | 22 |
| Atenolol | Atenolol | 132 | 30 |
| Glipizide Er | Glipizide | 132 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 126 | 32 |
| Loperamide | Loperamide Hcl | 124 | 98 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 123 | 55 |
| Donepezil Hcl | Donepezil Hcl | 123 | 42 |
| Hydrocortisone | Hydrocortisone | 121 | 39 |
| Pioglitazone Hcl | Pioglitazone Hcl | 106 | 26 |
| Furosemide | Furosemide | 104 | 25 |
| Ammonium Lactate | Ammonium Lactate | 93 | 32 |
| Celecoxib | Celecoxib | 92 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 92 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 91 | 86 |
| Montelukast Sodium | Montelukast Sodium | 89 | 20 |
| Meclizine Hcl | Meclizine Hcl | 85 | 38 |
| Spironolactone | Spironolactone | 84 | 20 |
| Fenofibrate | Fenofibrate | 83 | 23 |
| Glipizide | Glipizide | 83 | 22 |
| Januvia | Sitagliptin Phosphate | 78 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 75 | 23 |
| Trazodone Hcl | Trazodone Hcl | 74 | 26 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 73 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 73 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 15 |
| Divalproex Sodium Er | Divalproex Sodium | 67 | suppressed |
| Carvedilol | Carvedilol | 66 | 19 |
| Entecavir | Entecavir | 65 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 60 | 17 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 54 | 21 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 54 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 16 |
| Nifedipine Er | Nifedipine | 52 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 14 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 47 | 14 |
| Meloxicam | Meloxicam | 45 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 11 |
| Metformin Hcl Er | Metformin Hcl | 39 | 12 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 38 | 12 |
| Nitroglycerin | Nitroglycerin | 38 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | 11 |
| Naproxen | Naproxen | 34 | 17 |
| Clobetasol Propionate | Clobetasol Propionate | 33 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 33 | suppressed |
| Risperidone | Risperidone | 33 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 32 | 11 |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Lidocaine | Lidocaine | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Clotrimazole | Clotrimazole | 26 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Isoniazid | Isoniazid | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 21 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Fluocinonide | Fluocinonide | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Proctosol-Hc | Hydrocortisone | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Cholestyramine Light | Cholestyramine | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 13 |
| Prednisone | Prednisone | 15 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Peg-3350 And Electrolytes | Peg3350/Sod Sulf,bicarb,cl/Kcl | 12 | 12 |
| Pregabalin | Pregabalin | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Proctozone-Hc | Hydrocortisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,337.90 · 52 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FARXIGA, JARDIANCE, OTEZLA, PAXLOVID, REPATHA, REXULTI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error